| Dr Khalid Rayaz, MD | |
|
13212 Fairview Village Court, Little Rock, AR 72205-4417 | |
| (501) 257-1000 | |
| Not Available |
| Full Name | Dr Khalid Rayaz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 49 Years |
| Location | 13212 Fairview Village Court, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023107935 | NPI | - | NPPES |
| 180380001 | Medicaid | AR | |
| P01120993 | Other | AR | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | E-4732 (Arkansas) | Primary |
| 207PE0004X | Emergency Medicine - Emergency Medical Services | E4732 (Arkansas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred Hospice I | Hot springs, AR | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhg L Llc | 0547699225 | 14 |
| Primary Care 360 | 4183050842 | 3 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588654016 PECOS PAC ID: 4082528955 Enrollment ID: O20031219000706 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | St Vincent Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134176480 PECOS PAC ID: 5698758803 Enrollment ID: O20040622000224 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427149814 PECOS PAC ID: 0143134270 Enrollment ID: O20050406001290 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Neurology Clinic Of South Arkansas,pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124032560 PECOS PAC ID: 5698790335 Enrollment ID: O20051011001001 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | South Arkansas Emergency Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942435458 PECOS PAC ID: 4486705720 Enrollment ID: O20090629000005 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Harris Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659608040 PECOS PAC ID: 2365584331 Enrollment ID: O20100129000011 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | White River Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578872297 PECOS PAC ID: 0143134270 Enrollment ID: O20110111000718 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Arkansas Pain Care Clinics, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467962118 PECOS PAC ID: 4385902105 Enrollment ID: O20171227000681 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Primary Care 360 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124678586 PECOS PAC ID: 4183050842 Enrollment ID: O20200129001002 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Bhg L Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699321406 PECOS PAC ID: 0547699225 Enrollment ID: O20200331003025 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | American Hope And Health Clinic Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538781208 PECOS PAC ID: 0547674293 Enrollment ID: O20210121000277 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Entity Name | Arkansas Vein Care Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518748367 PECOS PAC ID: 4385090026 Enrollment ID: O20231031003881 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Khalid Rayaz, MD 13212 Fairway Village Ct, Little Rock, AR 72212-4417 Ph: (870) 850-6053 | Dr Khalid Rayaz, MD 13212 Fairview Village Court, Little Rock, AR 72205-4417 Ph: (501) 257-1000 |
News Archive
Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.
Recent headlines have cast suspicion on social network analysis, which can mine data from the internet to target advertisements or potentially influence elections.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found striking differences in terminal care across different parts of the country.
› Verified 9 days ago
Lonnie E Harrison, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7 Shackleford West Blvd, Little Rock, AR 72211 Phone: 501-664-5860 Fax: 501-664-0889 | |
Muthu Veera Kumaran, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 556, Little Rock, AR 72205 Phone: 501-686-6033 Fax: 501-686-8932 | |
Armaghan Yunis Soomro, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 S Shackleford Rd, Little Rock, AR 72211 Phone: 501-219-7282 Fax: 201-277-9765 | |
Tanvi Harishbhai Patel, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 508, Little Rock, AR 72205 Phone: 501-686-7105 Fax: 501-526-5906 | |
Gaurav Dhar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Anthony R Giglia Iii, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5800 W 10th St, Ste 610 Freeway Medical Center, Little Rock, AR 72204 Phone: 501-661-9393 Fax: 501-663-4795 | |
Brian Bean, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: #2 St Vincent Circle, Little Rock, AR 72205 Phone: 501-552-3592 Fax: 501-552-4129 |